Facebook Linkedin Soundcloud Twitter Vimeo Xing
Home Tags PRO1184

Tag: PRO1184

First Patient Dosed with PRO1184 and PRO1160 Cleared for Study Initiation...

ADC Review | Editorial Team
Dosing has initiated in the Phase 1 first-in-human clinical trial of PRO1184 (NCT05579366),  an antibody-drug conjugates or ADC being developed by ProfoundBio comprising a folate receptor alpha-directed antibody conjugated to the exatecan payload using a novel, proprietary hydrophilic linker.

ProfoundBio Completes US $70 Million Series A+ Financing, Advancing Antibody-Drug Conjugate...

ADC Review | Editorial Team
China's ProfoundBio, a biotech company based in the Seattle area, WA, USA and Suzhou, China, focuses on the development of novel targeted therapies.  Earlier this week the...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X